USA struggles and middle income countries could do more in tackling health inequality according to Oxfam report
October 12, 2018Medical Communications Latin America, USA, health, inequality, oxfam
A cluster of Latin American countries such as Costa Rica, Uruguay and Argentina, and a cluster of OECD countries with …
Living with Langerhans Cell Histiocytosis
October 11, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Langerhans Cell Histiocytosis, feature. pharma, patient experience, rare diseae
Affected as a young child by a rare disease which targets just one in 200,000 and led to neurodegeneration throughout …
Roche’s Ocrevus shows earlier, better outcomes in primary progressive and relapsing MS
October 11, 2018Research and Development Ocrevus, Roche, multiple sclerosis, pharma
Roche has unveiled new five-year data from three Phase 3 open-label extension studies investigating the efficacy of Ocrevus (ocrelizumab) in …
New US trade policy may limit foreign investment into biotechs
October 11, 2018Research and Development CIFUS, Trump, america, biotech, capital, foreign investment
The US Trump Administration have issued new rules, which will put foreign investment into companies involved in the development and …
Sequiris invest £40m into expansion of Liverpool plant creating 100 new jobs
October 11, 2018Manufacturing and Production, Research and Development Jobs, Vaccine, investment, liverpool
The Liverpool-based vaccine-maker Sequiris is investing £40 million into the expansion of its operations in the Speke area of Liverpool. …
Celltrion’s Rituxan biosimilar gets unanimous backing from FDA committee
October 11, 2018Sales and Marketing FDA, Oncologic Drugs Advisory Committee, Rituxan, Roche, Truxima
FDA approval looks to be in reach for Celltrion, as an advisory committee for the US regulator voted unanimously to …
Trump signs trust-busting biosimilar bill into law
October 11, 2018Business Services, Sales and Marketing FTC, Trump, biosimilars, generics, us politics
President Donald J Trump has signed off a law which requires drugmakers and pharma firms to reveal the details of …
Manage Temperature Monitoring the EZ way with Woodley…
October 10, 2018Investigational Medicinal Product, Temperature Monitoring, clinical trials
Manage Temperature Monitoring the EZ way with Woodley…As Clinical Trials protocols become ever more complex so too has the need …
Increased funding and research could help address unmet mental health needs
October 10, 2018Research and Development funding, global data, mental health, research
Unmet needs relating to mental health could be met through increasing funding and research, according to data analytics firm GlobalData. …
NICE recommends first new X-linked hypophosphataemia therapy in over 30 years
October 10, 2018Research and Development, Sales and Marketing Crysvita, Kyowa Kirin International, NHS, NICE, X-linked hypophosphataemia, pharma
NICE has announced its evidence-based recommendation that Kyowa Kirin International’s Crysvita (burosumab) be made available on the NHS for the …
Sackler-owned Mundipharma acquires biosimilar firm Cinfa Biotech
October 10, 2018Research and Development Mundipharma, biosimilar, cinfa biotech, sackler
In a bid to strengthen their biosimilar portfolio, the Cambridge based pain management company Mundipharma has acquired biosimilar development firm …
Novartis’ sickle cell drug reduces vaso-occlusive crises by 35% at Phase 2
October 10, 2018Research and Development Novartis, crizanlizumab, pharma, sickle cell disease
Novartis has presented new Phase 2 data for its humanised anti-P-selectin monoclonal antibody crizanlizumab in the treatment of sickle cell …
WHO voices concern over British immigration policies after researchers refused entry
October 10, 2018Research and Development WHO, academia, immigration, research, universities
The World Health Organization (WHO) has expressed concern over the UK’s immigration polices, after a number of academics were refused …
Non-profit generic drug company Civica Rx appoints former Amgen quality chief as new CEO
October 9, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbot, Amgen, Bayer, civica rx, generic drugs, hospitals
Civica Rx, a new not-for-profit generic drug company aimed at reducing the price of lifesaving medicines, has appointed former Amgen …
Menlo Therapeutics’ cough drug fails to meet primary endpoint in phase II trial
October 9, 2018Manufacturing and Production Phase II, cough, menlo therapeutics, serlopitant
The Redwood City, California-based late stage biopharmaceutical company Menlo Therapeutics have announced that experimental drug serlopitant has failed to meet …
Janssen’s Stelara shows promise across two dosages in ulcerative colitis
October 9, 2018Manufacturing and Production, Research and Development Janssen, Stelara, pharma, ulcerative colitis
Janssen’s biologic therapy Stelara (ustekinumab) has shown new efficacy in the treatment of moderate to severe ulcerative colitis in two …
NICE guidelines on antidepressant withdrawal symptoms are misleading, study shows
October 9, 2018Manufacturing and Production NICE, UK, addiction, antidepressants, research, study
Current NICE guidance concerning the severity of the effects of antidepressant withdrawal is misleading doctors according to research published in …
Celgene’s Otezla impresses at Phase 3 in scalp psoriasis
October 9, 2018Manufacturing and Production, Research and Development Celgene, pharma, psoriasis
Celgene has unveiled new Phase 3 data for Otezla (apremilast), its inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine …
New hospital-led organisation aims to tackle drug pricing problem by manufacturing generic drugs
October 9, 2018Manufacturing and Production PhRMA, aha, generics, hospitals, non profit, non-profit, pharma
Seven organisations representing around 500 US hospitals have become the governing members of a newly established initiative aimed at reducing …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
